Analyst RecommendationFirst stock in the clip. GLTA
https://www.bnn.ca/Video/player.aspx?vid=847352
MSL-T 2016-04-11 BUY James Telfser
In the specialty Pharma space, which has had a lot of troubles. Multiples have contracted quite a bit. Compared to their competitors, they have had a much cleaner balance sheet. Haven’t actually made their big acquisitions yet to load up the balance sheet with debt. They were able to raise about $30 million earlier this year. New management has executed well on the deals and their European jurisdiction. At this level, it is a pretty compelling Buy, but you have to be willing to ride out the volatility from headlines.
Login to show your approval Login to show your disapproval / Be the first to comment
Price:
$1.950
Subject:
CANADIAN
Bias:
OPTIMISTIC
Owned:
Yes